by TractManager | Mar 27, 2023 | Emerging Technology Report
Etranacogene dezaparvovec (Hemgenix; formerly AMT-061) is an adeno-associated virus vector-based gene therapy indicated for the treatment of adults with hemophilia B (congenital factor IX deficiency) who currently use factor IX prophylaxis therapy, have current or...
by TractManager | Mar 24, 2023 | Molecular Test Assessment
This report evaluates the clinical validity and clinical utility of the Cologuard test (Exact Sciences Corp.).If you have a Hayes login, click here to view the full report on the Knowledge Center.
by TractManager | Mar 17, 2023 | Emerging Technology Report
Zavegepant is an intranasal novel small-molecule, calcitonin gene-related peptide (CGRP) receptor antagonist indicated for the acute treatment of migraine with or without aura in adults.If you have a Hayes login, click here to view the full report on the Knowledge...
by TractManager | Mar 16, 2023 | Emerging Technology Report
Omecamtiv mecarbil is a first-in-class oral cardiac myosin activator under investigation for the treatment of heart failure with reduced ejection fraction (HFrEF).If you have a Hayes login, click here to view the full report on the Knowledge Center.
by TractManager | Mar 15, 2023 | Emerging Technology Report
Trofinetide (Daybue) is an oral synthetic glypromate analog indicated for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older.If you have a Hayes login, click here to view the full report on the Knowledge Center.
Recent Comments